Western Blot: 0,25 - 0,5 μg/mL. Immunohistochemistry: 5 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS, 0.02 % Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Storage Comment
Store the antibody undiluted at 2-8 °C.
Target
RANKL (TNFSF11)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 11 (TNFSF11))
OPG ligand (OPGL,) a type II membrane protein, binds to a unique hematopoietic progenitor cell that is committed to the osteoclast lineage and stimulates the rapid induction of genes involved in osteoclast development. OPGL is expressed in the primitive mesenchymal cells, in hypertrophying chondrocytes and in areas undergoing primary ossification and modeling. This gene was independently isolated and called RANKL (receptor activator of NF-Kappa B ligand). RANKL was shown to augument the ability of dendritic cells to stimulate naive T-cell proliferation. A soluble form of the protein consisting of only the extracellular domain is called TRANCE.Synonyms: ODF, OPGL, Osteoclast differentiation factor, Osteoprotegerin ligand, RANK Ligand, RANKL, Receptor activator of nuclear factor kappa B ligand, TNF-related activation-induced cytokine, TNFSF11, TRANCE, Tumor necrosis factor ligand superfamily member 11